Cinacalcet
- PDF / 169,295 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 69 Downloads / 121 Views
1 S
Acute and severe hypocalcaemia following off-label use: case report In a retrospective study involving 20 paediatric patients from the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) Registry, an approximately 25-year-old man was described, who developed acute and severe hypocalcaemia following off-label treatment with cinacalcet for post-transplant secondary hyperparathyroidism. The man, who had congenital anomalies of the kidney and urinary tract, underwent renal transplantation at pre-emptive stage at the age of 18.8 year. Additionally, he had persistent secondary hyperparathyroidism. At the time of transplant, his calcium level was 2.7 mmol/L. After 3 years of transplant, he started receiving off-label treatment with cinacalcet 1.9 mg/kg daily for secondary hyperparathyroidism. Following 6.5 years of transplant, and 3.5 years of cinacalcet initiation, at the approximate age of 25 years, he developed acute and severe hypocalcaemia (calcium 1.80 mmol/L) as an adverse effect of cinacalcet. The man’s treatment with cinacalcet was discontinued [outcome not stated]. Bernardor J, et al. The use of cinacalcet after pediatric renal transplantation: an international CERTAIN Registry analysis. Pediatric Nephrology 35: 1707-1718, No. 9, Sep 803499856 2020. Available from: URL: http://doi.org/10.1007/s00467-020-04558-8
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
